This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumpti ...

Company Overview - MAIA Biotechnology, Inc. is a biotechnology company founded in 2018 and headquartered in Chicago, Illinois, focused on discovering, developing, and commercializing novel cancer therapies addressing high unmet medical needs [2]. Recent Developments - MAIA Biotechnology advanced its lead candidate, ateganosine (THIO), with significant progress in clinical, regulatory, and pipeline fronts during Q2 2025 [4]. - The pivotal Phase 2 THIO-101 study in advanced non-small cell lung cancer (NSCLC) reported a median overall survival of 17.8 months among 22 third-line patients, with treatment being generally well tolerated [4]. - A new partial response was confirmed after 20 months of therapy, indicating the potential effectiveness of the treatment [4]. - The trial has expanded into Asia, with first dosing in Taiwan and ongoing screening in Europe and Asia [4]. - MAIA entered a master clinical supply agreement with Roche to evaluate ateganosine in combination with atezolizumab (Tecentriq®) across multiple hard-to-treat cancers [4]. - The FDA granted Fast Track designation for ateganosine in the treatment of NSCLC, enhancing the regulatory path for the drug [4]. Future Plans - MAIA plans to initiate studies in various cancers beyond NSCLC, including hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), colorectal cancer (CRC), breast, prostate, gastric, pancreatic, and ovarian cancers [4]. - The company aims to evaluate THIO-103 for first-line NSCLC and SCLC [4]. Valuation Insights - Recent updates have de-risked the THIO program in third-line NSCLC, with the Phase 2 THIO-101 dataset supporting a generally tolerable safety profile and durability of response [4]. - The valuation model has been revised to reflect recent financial results and share count, yielding a valuation of $10.27 per share, contingent on successful execution by the company [4].

Core Insights - Spartan Capital Securities, LLC announced the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. [1] - The offering involved the sale of 974,026 shares of Common Stock at a public offering price of $1.54 per share [2] - The gross proceeds of approximately $1.5 million will be used for general corporate purposes and working capital [3] Company Overview - Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on cancer drug development [2][8] - The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that enhances the effectiveness of chemotherapy and immunotherapy [8] - Clinical trials are currently underway for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [8] Transaction Details - The offering was made under an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission [5] - Spartan Capital Securities served as the exclusive placement agent for this transaction [1][4] - The transaction reflects a focus on aligning innovative biotech companies with strategic capital for advancing therapies [4]

Core Insights - Crescent Biopharma, Inc. has completed its merger with GlycoMimetics, Inc. and will trade under the ticker symbol "CBIO" on Nasdaq starting June 16, 2025 [1][2] - The company has raised $200 million in a private financing round, which will support operations through 2027 and facilitate multiple pipeline milestones [1][3] - Crescent is advancing its lead program, CR-001, a PD-1 x VEGF bispecific antibody, with an IND application expected in Q4 2025 and proof-of-concept clinical data anticipated in H2 2026 [3][4] Company Overview - Crescent Biopharma aims to become a leading oncology company by developing innovative therapies for cancer patients, including its lead program and novel antibody-drug conjugates (ADCs) [4] - The company plans to leverage multiple modalities and established targets to advance transformative therapies for solid tumors [4] Pipeline Development - CR-001 is designed to replicate the pharmacology of ivonescimab, which has shown superior efficacy compared to pembrolizumab in a Phase 3 trial for non-small cell lung cancer [3][7] - The company is also developing two novel ADCs, CR-002 and CR-003, with CR-002 expected to enter clinical trials in mid-2026 [3]